More tools:Markets·Screener·Research·Chat

Nuvation Bio Inc. (NUVB) Financial Statements

Nuvation Bio Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00VHJ0CD0
XNYS · usd
6.61▼ 0.20 (-2.94%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close6.81
Day's Range6.58 – 6.75
52-Week Range2.99 – 9.75
Volume2.5M
Avg Volume5.2M
Share Statistics
Shares Outstanding
Employees298
ExchangeXNYS
Listed2021-02-10
Share count as of August 3, 2026
Loading Income Statement…
Key questions about Nuvation Bio Inc. (NUVB)
What is Nuvation Bio Inc.'s Market Cap?
Nuvation Bio Inc.'s Market Cap is $2.3B, based on as-reported figures from SEC (XBRL) filings.
What is Nuvation Bio Inc.'s Enterprise Value?
Nuvation Bio Inc.'s Enterprise Value is $1.9B, based on as-reported figures from SEC (XBRL) filings.
What is Nuvation Bio Inc.'s Price / Sales?
Nuvation Bio Inc.'s Price / Sales is 13.7×, based on as-reported figures from SEC (XBRL) filings.
What is Nuvation Bio Inc.'s EV / Revenue?
Nuvation Bio Inc.'s EV / Revenue is 11.2×, based on as-reported figures from SEC (XBRL) filings.
What is Nuvation Bio Inc.'s EV / EBITDA?
Nuvation Bio Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Nuvation Bio Inc.'s Revenue (TTM)?
Nuvation Bio Inc.'s Revenue (TTM) is $169.9M, based on as-reported figures from SEC (XBRL) filings.
What is Nuvation Bio Inc.'s Net Income (TTM)?
Nuvation Bio Inc.'s Net Income (TTM) is -$149.8M, based on as-reported figures from SEC (XBRL) filings.
What is Nuvation Bio Inc.'s EBITDA?
Nuvation Bio Inc.'s EBITDA is -$135.5M, based on as-reported figures from SEC (XBRL) filings.
What is Nuvation Bio Inc.'s Diluted EPS (TTM)?
Nuvation Bio Inc.'s Diluted EPS (TTM) is -0.43, based on as-reported figures from SEC (XBRL) filings.
What is Nuvation Bio Inc.'s EBITDA Margin?
Nuvation Bio Inc.'s EBITDA Margin is -79.7%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth+555.6%+2598.7%+633.1%+1704.7%
Costs and expenses:
Cost of sales——
Cost of collaboration and license agreements revenue——
Research and development
Selling, general and administrative
Total costs and expenses
% of revenue261.1%95.3%200.5%504.6%
Loss from operations
% of revenue-161.1%4.7%-81.3%-430.1%
Other income (expense):
Interest income
Interest expense
Investment advisory fees
Loss on debt extinguishment———
Change in fair value of warrant liability
Realized gain (loss) on marketable securities
Other income—
Total other (expense) income, net
Income (loss) before income taxes
Provision for income taxes
Net loss
% of revenue-198.3%6.5%-87.4%-425.2%
Basic earnings (loss) per share attributable to common stockholders—
Diluted earnings (loss) per share attributable to common stockholders—